Stock
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) TAK
Overview
TAK market data
Price History
TAK price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$96.75 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.30 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 348.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4,102.00 – $6,033.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $9.2M · P/B 1.21 · P/S 2.03.
Company News
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B EstBenzinga · Jul 30, 2026, 12:11 PM
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585BBenzinga · Jul 30, 2026, 7:46 AM
Takeda Pharmaceutical Co Lowers FY2026 Adj EPS Guidance from $3.01 to $2.96 vs $1.57 Est; Lowers FY2026 Sales Guidance from $29.585B to $29.116B vs $28.950B EstBenzinga · Jul 30, 2026, 7:44 AM
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B EstimateBenzinga · Jul 30, 2026, 6:49 AM
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026Globenewswire Inc · Jul 27, 2026, 11:00 AM
[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Globenewswire Inc · Jul 22, 2026, 6:15 PM
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in TrialsBenzinga · Jul 17, 2026, 5:08 PM
Takeda shares are trading higher after the company announced that Phase 3 data from two studies of Zasocitinib in adults with plaque psoriasis indicate consistent and high skin clearance rates.Benzinga · Jul 17, 2026, 2:22 PM
Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin ClearanceBenzinga · Jul 17, 2026, 2:19 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM